Curis Lifesciences Limited (NSE:CURIS)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019
Drug Delivery Systems	496.32M	355.56M	354.49M	237.45M	212.60M
Drug Delivery Systems Growth	39.59%	0.30%	49.29%	11.69%	55.26%
Total	496.32M	355.56M	354.49M	237.45M	212.60M
Total Growth	39.59%	0.30%	49.29%	11.69%	55.26%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019
India	477.88M	340.56M	333.70M	72.48M	212.60M
India Growth	40.32%	2.06%	360.43%	-65.91%	55.26%
Export	131.00K	2.00M	3.56M	-	-
Export Growth	-93.46%	-43.75%	-	-	-
Other	13.31M	13.00M	17.23M	-	-
Other Growth	2.42%	-24.56%	-	-	-
Rwanda	-	-	-	43.53M	-
Myanmar	-	-	-	19.07M	-
Kenya	-	-	-	16.14M	-
Uzbekistan	-	-	-	398.00K	-
Malawi	-	-	-	6.45M	-
United Kingdom	-	-	-	2.67M	-
Nigeria	-	-	-	1.80M	-
Sierra Leone	-	-	-	11.42M	-
Tazakistan	-	-	-	4.38M	-
Peru	-	-	-	1.35M	-
Mali	-	-	-	4.80M	-
Afghanistan	-	-	-	562.00K	-
Panama	-	-	-	3.19M	-
Angola	-	-	-	11.05M	-
Barbadosa	-	-	-	1.94M	-
DRC	-	-	-	12.59M	-
Total	491.32M	355.56M	354.49M	213.80M	212.60M
Total Growth	38.18%	0.30%	65.80%	0.56%	55.26%

Source: S&P Global Market Intelligence.